News & AnalysisImvax locks in $112m Series CPhiladelphia-based Imvax, a biotechnology company, has closed $112 million in Series C financing.ByIris Dorbian17 July 2020•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs